<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00160966</url>
  </required_header>
  <id_info>
    <org_study_id>NTx-PV-002</org_study_id>
    <nct_id>NCT00160966</nct_id>
  </id_info>
  <brief_title>Impact of Immunosuppressive Regimens on Polyomavirus-related Transplant Nephropathy</brief_title>
  <official_title>Prospective Randomized Study to Characterize Risk Factors of Polyomavirus-related Transplant Nephropathy and the Impact of Three Immunosuppressive Regimens on Nephropathy Incidence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to characterize and evaluate risk factors of polyomavirus
      nephropathy (PVN) including the impact of three immunosuppressive regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polyomavirus nephropathy (PVN) is an emerging cause of renal transplant loss. Until now the
      risk factors of PVN are poorly understood. Tacrolimus (Tacr) and mycophenolate mofetil (MMF)
      are thought to be associated with a higher risk of developing PVN. However, the way in which
      Tacr or MMF might enhance the susceptibility for PVN remains largely unknown. In this
      prospective study we will analyze whether differences in immune-reactivity patterns (Th1,
      Th2, B cell and monocyte responses, sCD30, immunoregulatory antibodies) of renal transplant
      patients induced by different immunosuppressive regimens (cyclosporine A [CsA]/MMF, Tacr/MMF,
      Tacr/MMF with conversion to Tacr/Everolimus [ERL]) or by cytokine promoter gene polymorphisms
      may account for the different risks of developing PVN.

      Comparison(s): renal transplant recipients stratified according to their relative
      immunological risk (group 1: low risk (primary recipients without pre-immunization [PRA &lt;
      5%]); group 2: moderate risk (group 2a: primary recipients with low pre-immunization [PRA
      6-20%]; group 2b: re-transplanted patients); group 3: very high risk (re-transplanted
      patients with a history of vascular rejection or recipients of a first graft with high
      pre-immunization [PRA &gt; 20%]) randomized to be treated with one of three immunosuppressive
      regimens (CsA/MMF, Tacr/MMF, Tacr/MMF with subsequent conversion to Tacr/ERL).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of polyomavirus associated transplant nephropathy (PVN)</measure>
    <time_frame>2 years posttransplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of polyoma viremia</measure>
    <time_frame>2 years posttransplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>urine polyomavirus concentration within the first two years post-transplant</measure>
    <time_frame>2 years posttransplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>patients' and grafts' survival</measure>
    <time_frame>2 years posttransplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of acute rejections</measure>
    <time_frame>2 years posttransplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transplant function 1 and 2 years post-transplant</measure>
    <time_frame>2 years posttransplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of urine cytology and polymerase chain reaction (PCR) quantitative data regarding diagnosis of PVN</measure>
    <time_frame>2 years posttransplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predictive value of immune parameters prognostically relevant for acute or chronic rejection</measure>
    <time_frame>2 years posttransplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects of immunosuppressive drugs</measure>
    <time_frame>2 years posttransplant</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Polyomavirus Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immunosuppression with Ciclosporin and Mycophenolate-mofetil; Ciclosporin treatment being started at the latest at day 4 after transplantation with 7 mg/kg body weight daily administered every 8 hours until the target trough level of 300 µg/l was reached. Then it was administered twice daily with daily monitoring of trough levels. The target trough level was lowered to 200 µg/l 1 month after transplantation. Thereafter dosage and target trough levels were adjusted at the investigators discretion. Mycophenolate-mofetil was started previous to transplantation procedure with a starting dosage of 3 g/day administered twice daily. Once ciclosporin was entered into the therapy-scheme Mycophenolate-mofetil dosage was reduced to 2 g/daily. The therapy was controlled by measuring of trough levels with a target trough level exceeding 1 µg/ml. The dosage was adjusted at the investigators discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immunosuppression with Tacrolimus and Mycophenolate-mofetil Mycophenolate-mofetil was started previous to transplantation procedure with a starting dosage of 3 g/day administered twice daily. Once tacrolimus was entered into the therapy-scheme Mycophenolate-mofetil dosage was reduced to 2 g/daily. The therapy was controlled by measuring of trough levels with a target trough level exceeding 1 µg/ml. The dosage was adjusted to clinical signs of overimmunosuppression (infections) or intolerance (mainly gastrointestinal side effects) or rejections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immunosuppression with Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus after completion of posttransplant wound healing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporin and Mycophenolate-mofetil</intervention_name>
    <description>according to the Giessen protocol</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus and Mycophenolate-mofetil</intervention_name>
    <description>according to Giessen protocol</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus</intervention_name>
    <description>according to Giessen protocol</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cadaver kidney and living donor kidney transplant recipients

          -  Primary, secondary, and tertiary transplant recipients

          -  Pre-immunized and not pre-immunized transplant recipients

          -  Age &gt; 18 years

        Exclusion Criteria:

          -  Contraindications against administration of one of the four study drugs

          -  History of severe gastrointestinal morbidity

          -  Age &lt; 18 years

          -  Pregnant or breast feeding women

          -  Rejection of effective contraceptive methods with young women

          -  Combined kidney and islet cell transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf Weimer, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Giessen, Internal Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine, University of Giessen</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Andrews CA, Shah KV, Daniel RW, Hirsch MS, Rubin RH. A serological investigation of BK virus and JC virus infections in recipients of renal allografts. J Infect Dis. 1988 Jul;158(1):176-81.</citation>
    <PMID>2839580</PMID>
  </reference>
  <reference>
    <citation>Barri YM, Ahmad I, Ketel BL, Barone GW, Walker PD, Bonsib SM, Abul-Ezz SR. Polyoma viral infection in renal transplantation: the role of immunosuppressive therapy. Clin Transplant. 2001 Aug;15(4):240-6.</citation>
    <PMID>11683817</PMID>
  </reference>
  <reference>
    <citation>Nickeleit V, Hirsch HH, Zeiler M, Gudat F, Prince O, Thiel G, Mihatsch MJ. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant. 2000 Mar;15(3):324-32. Review.</citation>
    <PMID>10692517</PMID>
  </reference>
  <reference>
    <citation>Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, Steiger J. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002 Aug 15;347(7):488-96.</citation>
    <PMID>12181403</PMID>
  </reference>
  <reference>
    <citation>Hirsch HH. Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation. Am J Transplant. 2002 Jan;2(1):25-30. Review.</citation>
    <PMID>12095052</PMID>
  </reference>
  <reference>
    <citation>Hirsch HH, Mohaupt M, Klimkait T. Prospective monitoring of BK virus load after discontinuing sirolimus treatment in a renal transplant patient with BK virus nephropathy. J Infect Dis. 2001 Dec 1;184(11):1494-5; author reply 1495-6.</citation>
    <PMID>11709797</PMID>
  </reference>
  <reference>
    <citation>Binet I, Nickeleit V, Hirsch HH, Prince O, Dalquen P, Gudat F, Mihatsch MJ, Thiel G. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation. 1999 Mar 27;67(6):918-22.</citation>
    <PMID>10199744</PMID>
  </reference>
  <reference>
    <citation>Weimer R, Süsal C, Yildiz S, Streller S, Pelzl S, Staak A, Renner F, Dietrich H, Daniel V, Feuring E, Kamali-Ernst S, Ernst W, Padberg W, Opelz G. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil. Transplant Proc. 2005 May;37(4):1776-8.</citation>
    <PMID>15919463</PMID>
  </reference>
  <reference>
    <citation>Weimer R, Staak A, Süsal C, Streller S, Yildiz S, Pelzl S, Renner F, Dietrich H, Daniel V, Rainer L, Kamali-Ernst S, Ernst W, Padberg W, Opelz G. ATG induction therapy: long-term effects on Th1 but not on Th2 responses. Transpl Int. 2005 Feb;18(2):226-36.</citation>
    <PMID>15691277</PMID>
  </reference>
  <reference>
    <citation>Weimer R, Mytilineos J, Feustel A, Preiss A, Daniel V, Grimm H, Wiesel M, Opelz G. Mycophenolate mofetil-based immunosuppression and cytokine genotypes: effects on monokine secretion and antigen presentation in long-term renal transplant recipients. Transplantation. 2003 Jun 27;75(12):2090-9.</citation>
    <PMID>12829918</PMID>
  </reference>
  <reference>
    <citation>Weimer R, Streller S, Staak A, Heilke M, Li D, Dietrich H, Daniel V, Feustel A, Rainer L, Zinn S, Friemann S, Ernst W, Grimm H, Padberg W, Zimmermann T, Opelz G. Effects of three immunosuppressive regimens on CD4 helper function, B cell monocyte and cytokine responses in renal transplant recipients: 4-month follow-up of a prospective randomized study. Transplant Proc. 2002 Sep;34(6):2377-8.</citation>
    <PMID>12270445</PMID>
  </reference>
  <reference>
    <citation>Weimer R, Melk A, Daniel V, Friemann S, Padberg W, Opelz G. Switch from cyclosporine A to tacrolimus in renal transplant recipients: impact on Th1, Th2, and monokine responses. Hum Immunol. 2000 Sep;61(9):884-97.</citation>
    <PMID>11053632</PMID>
  </reference>
  <reference>
    <citation>Daniel V, Arzberger J, Melk A, Weimer R, Ruhenstroth A, Carl S, Wiesel M, Opelz G. Predictive indicators of rejection or infection in renal transplant patients. Transplant Proc. 1999 Feb-Mar;31(1-2):1364-5.</citation>
    <PMID>10083605</PMID>
  </reference>
  <reference>
    <citation>Weimer R, Zipperle S, Daniel V, Carl S, Staehler G, Opelz G. Pretransplant CD4 helper function and interleukin 10 response predict risk of acute kidney graft rejection. Transplantation. 1996 Dec 15;62(11):1606-14.</citation>
    <PMID>8970616</PMID>
  </reference>
  <reference>
    <citation>Daniel V, Pasker S, Wiesel M, Carl S, Pomer S, Staehler G, Schnobel R, Weimer R, Opelz G. Cytokine monitoring of infection and rejection in renal transplant recipients. Transplant Proc. 1995 Feb;27(1):884-6.</citation>
    <PMID>7879219</PMID>
  </reference>
  <reference>
    <citation>Weimer R, Zipperle S, Daniel V, Pomer S, Staehler G, Opelz G. IL-6 independent monocyte/B cell defect in renal transplant recipients with long-term stable graft function. Transplantation. 1994 Jan;57(1):54-9.</citation>
    <PMID>7507271</PMID>
  </reference>
  <reference>
    <citation>Weimer R, Daniel V, Zimmermann R, Schimpf K, Opelz G. Autoantibodies against CD4 cells are associated with CD4 helper defects in human immunodeficiency virus-infected patients. Blood. 1991 Jan 1;77(1):133-40.</citation>
    <PMID>1824617</PMID>
  </reference>
  <reference>
    <citation>Weimer R, Daniel V, Pomer S, Opelz G. B lymphocyte response as an indicator of acute renal transplant rejection. II. Pretransplant and posttransplant B cell responses of m mitogen and donor cell-stimulated cultures. Transplantation. 1989 Oct;48(4):572-5.</citation>
    <PMID>2678634</PMID>
  </reference>
  <reference>
    <citation>Weimer R, Daniel V, Pomer S, Opelz G. B lymphocyte response as an indicator of acute renal transplant rejection. I. Immunoglobulin-secreting cells in peripheral blood. Transplantation. 1989 Oct;48(4):569-72.</citation>
    <PMID>2572082</PMID>
  </reference>
  <reference>
    <citation>Süsal C, Döhler B, Opelz G. Graft-protective role of high pretransplantation IgA-anti-Fab autoantibodies: confirmatory evidence obtained in more than 4000 kidney transplants. The Collaborative Transplant Study. Transplantation. 2000 Apr 15;69(7):1337-40.</citation>
    <PMID>10798750</PMID>
  </reference>
  <reference>
    <citation>Pelzl S, Opelz G, Daniel V, Wiesel M, Süsal C. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation. 2003 Feb 15;75(3):421-3.</citation>
    <PMID>12589170</PMID>
  </reference>
  <reference>
    <citation>Süsal C, Pelzl S, Döhler B, Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol. 2002 Jun;13(6):1650-6.</citation>
    <PMID>12039995</PMID>
  </reference>
  <reference>
    <citation>Süsal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation. 2002 Apr 27;73(8):1269-73.</citation>
    <PMID>11981420</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Giessen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Rolf Weimer</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>kidney transplantation</keyword>
  <keyword>polyoma virus associated transplant nephropathy</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>mycophenolate mofetil</keyword>
  <keyword>everolimus</keyword>
  <keyword>cyclosporin A</keyword>
  <keyword>BK virus PCR</keyword>
  <keyword>viruria screening</keyword>
  <keyword>BK polyomavirus</keyword>
  <keyword>immunosuppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polyomavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data of all participants will be made available within 1 year of study completion.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

